Autoimmune heparin‐induced thrombocytopenia (aHIT) indicates the presence in patients of
anti‐platelet factor 4 (PF4)–polyanion antibodies that are able to activate platelets strongly …

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an
increasing incidence. Despite the changing landscape of VTE treatment with the introduction …

Venous thromboembolism (VTE) is a common complication in patients with malignant
disease. Emerging data have enhanced our understanding of cancer-associated …

Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

The article presents information on the diagnosis of the heparin-induced thrombocytopenia
(HIT). It informs about the diagnosis techniques used for HIT which includes enzyme-linked …

Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, is
associated with a considerable disease burden which continues to grow along with the …

Heparin-induced thrombocytopenia is a prothrombotic adverse drug effect induced by
platelet-activating antibodies against multimolecular complexes of platelet factor 4 and …

Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet-
activating IgG antibodies that recognize platelet factor 4 (PF4)/polyanion complexes. Platelet …

Current guidelines for heparin-induced thrombocytopenia (HIT) management recommend
heparin cessation and switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) …

Autoimmune thrombocytopenia (aHIT) is a severe subtype of heparin-induced
thrombocytopenia (HIT) with atypical clinical features caused by highly pathological IgG …